
ICCM Stock Forecast & Price Target
ICCM Analyst Ratings
Bulls say
Icecure Medical Ltd reported a significant 102% growth in total revenue for the third quarter of 2024, reaching $0.7 million, which aligns with projections and reflects robust demand for its cryoablation products. Sales of ProSense systems and disposable probes saw a 36% increase to $2.3 million for the first nine months of 2024, driven by expansion in key markets across Europe, the U.S., Japan, and Asia, indicating a strong international presence. Furthermore, the recent FDA marketing authorization for the XSense system underscores the viability of Icecure's cryoablation technology, potentially bolstering its market position and paving the way for further growth pending upcoming regulatory decisions.
Bears say
Icecure Medical Ltd faces significant challenges that contribute to a negative outlook on its stock, primarily due to the risk of its cryoablation systems failing to achieve commercial success in a competitive market. The company confronts potential setbacks, including failures in clinical trials and the possibility of not obtaining necessary regulatory approvals in the U.S., which could further hinder its market penetration. Additionally, concerns regarding dilution risk diminish investor confidence and complicate the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Icecure Medical Ltd and is not a guaranteed prediction by Public.com or investment advice.
ICCM Analyst Forecast & Price Prediction
Start investing in ICCM
Order type
Buy in
Order amount
Est. shares
0 shares